Terms: = Kidney tumors AND RB1, OSRC, ENSG00000139687, 5925, RB, P06400 AND Prognosis
17 results:
1. Gene mutation profiling and clinical significances in patients with renal cell carcinoma.
Wang Y; He P; Zhou X; Wang C; Fu J; Zhang D; Liao D; Zhou Z; Wu C; Gong W
Clinics (Sao Paulo); 2023; 78():100259. PubMed ID: 37515929
[TBL] [Abstract] [Full Text] [Related]
2. Chromophobe Renal Cell Carcinoma with Sarcomatoid Differentiation: Clinicopathologic Correlation and Molecular Findings.
Gama A; Xu H; Yang XJ; Choy B
Int J Surg Pathol; 2024 Feb; 32(1):11-16. PubMed ID: 37063043
[No Abstract] [Full Text] [Related]
3. A machine learning framework develops a DNA replication stress model for predicting clinical outcomes and therapeutic vulnerability in primary prostate cancer.
Huang RH; Hong YK; Du H; Ke WQ; Lin BB; Li YL
J Transl Med; 2023 Jan; 21(1):20. PubMed ID: 36635710
[TBL] [Abstract] [Full Text] [Related]
4. [Expression and significance of fibroblast growth factor receptor 2 in clear cell renal cell carcinoma].
Cai TY; Zhu ZP; Xu CR; Ji X; Lv TD; Guo ZK; Lin J
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):628-635. PubMed ID: 35950384
[TBL] [Abstract] [Full Text] [Related]
5. Dose escalation study of targeted alpha therapy with [
Królicki L; Bruchertseifer F; Kunikowska J; Koziara H; Pawlak D; Kuliński R; Rola R; Merlo A; Morgenstern A
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3595-3605. PubMed ID: 33860346
[TBL] [Abstract] [Full Text] [Related]
6. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
[No Abstract] [Full Text] [Related]
7. Prevalence, clinical features and prognosis of malignant solid tumors in infants: a 14-year study.
Zhi T; Zhang WL; Zhang Y; Wang YZ; Huang DS
Bosn J Basic Med Sci; 2021 Oct; 21(5):598-606. PubMed ID: 33259778
[TBL] [Abstract] [Full Text] [Related]
8. Primary round cell sarcomas of the urinary bladder with EWSR1 rearrangement: a multi-institutional study of thirteen cases with a review of the literature.
Baisakh MR; Tiwari A; Gandhi JS; Naik S; Sharma SK; Balzer BL; Sharma S; Peddinti K; Jha S; Sahu PK; Pradhan D; Geller M; Amin MB; Dhillon J; Mohanty SK
Hum Pathol; 2020 Oct; 104():84-95. PubMed ID: 32798549
[TBL] [Abstract] [Full Text] [Related]
9. Identification of CXCL13 as a potential biomarker in clear cell renal cell carcinoma via comprehensive bioinformatics analysis.
Xu T; Ruan H; Song Z; Cao Q; Wang K; Bao L; Liu D; Tong J; Yang H; Chen K; Zhang X
Biomed Pharmacother; 2019 Oct; 118():109264. PubMed ID: 31390578
[TBL] [Abstract] [Full Text] [Related]
10. MicroRNA-200b is downregulated and suppresses metastasis by targeting LAMA4 in renal cell carcinoma.
Li Y; Guan B; Liu J; Zhang Z; He S; Zhan Y; Su B; Han H; Zhang X; Wang B; Li X; Zhou L; Zhao W
EBioMedicine; 2019 Jun; 44():439-451. PubMed ID: 31130475
[TBL] [Abstract] [Full Text] [Related]
11. HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas.
Sun M; Tong P; Kong W; Dong B; Huang Y; Park IY; Zhou L; Liu XD; Ding Z; Zhang X; Bai S; German P; Powell R; Wang Q; Tong X; Tannir NM; Matin SF; Rathmell WK; Fuller GN; McCutcheon IE; Walker CL; Wang J; Jonasch E
Cancer Res; 2017 Oct; 77(19):5313-5326. PubMed ID: 28807937
[TBL] [Abstract] [Full Text] [Related]
12. High selectivity of PI3Kβ inhibitors in SETD2-mutated renal clear cell carcinoma.
Wang J; Wen J; Yi R; Liu F; Zhou J; Liu G; Li Q; Yang Z; Su X
J BUON; 2015; 20(5):1267-75. PubMed ID: 26537074
[TBL] [Abstract] [Full Text] [Related]
13. Clinical and tumor significance of tropomyosin-1 expression levels in renal cell carcinoma.
Wang J; Guan J; Lu Z; Jin J; Cai Y; Wang C; Wang F
Oncol Rep; 2015 Mar; 33(3):1326-34. PubMed ID: 25607530
[TBL] [Abstract] [Full Text] [Related]
14. [Renal tumors of childhood and adolescence associated with chromosomal anomalies].
Cajaiba MM; Reyes-Múgica M
Actas Urol Esp; 2007 Oct; 31(9):966-77. PubMed ID: 18257366
[TBL] [Abstract] [Full Text] [Related]
15. Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis.
Deeb KK; Michalowska AM; Yoon CY; Krummey SM; Hoenerhoff MJ; Kavanaugh C; Li MC; Demayo FJ; Linnoila I; Deng CX; Lee EY; Medina D; Shih JH; Green JE
Cancer Res; 2007 Sep; 67(17):8065-80. PubMed ID: 17804718
[TBL] [Abstract] [Full Text] [Related]
16. Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors.
DeCristofaro MF; Betz BL; Wang W; Weissman BE
Oncogene; 1999 Dec; 18(52):7559-65. PubMed ID: 10602515
[TBL] [Abstract] [Full Text] [Related]
17. Genetic approaches to the study of the molecular basis of human cancer.
Croce CM
Cancer Res; 1991 Sep; 51(18 Suppl):5015s-5018s. PubMed ID: 1653109
[TBL] [Abstract] [Full Text] [Related]
